Inhibition of human gastric carcinoma cell growth by treatment of N3-o-toluyl-fluorouracil as a precursor of 5-fluorouracil

European Journal of Pharmacology

Volumn 574, Issue 1, 2007, Pages 1-7

  Liu, Jian ^a,b   Li, Xun ^a   Cheng, Yan na ^a   Cui, Shu xiang ^c   Chen, Ming hui ^a   Xu, Wen fang ^a   Tian, Zhi gang ^a   Makuuchi, Masatoshi ^d   Tang, Wei ^a,d   Qu, Xian jun ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Traditional Chinese Medicine University   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^d University of Tokyo   (Japan)

Author keywords

5 fluorouracil; Apoptosis; Gastric carcinoma; Growth inhibition; N3 o toluyl fluorouracil (TFU)

Indexed keywords

ANTINEOPLASTIC AGENT; DNA FRAGMENT; FLUOROURACIL; LIVER ENZYME; MICROSOME ENZYME; N3 2 TOLUYL FLUOROURACIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RAT; STOMACH CARCINOMA; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; MICROSOMES, LIVER; PRODRUGS; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34848831140     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.06.064     Document Type: Article

References (30)

1. Berglund A., Carlsson G., Gustavsson B., Frodin J.E., Bagnhammar P., and Glimelius B. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma. Anticancer Res. 23 (2003) 1789-1794
2. Chang J.Y., Zhang X., Komaki R., Cheung R., and Fang B. Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys. 64 (2006) 1482-1494
3. Cui S.X., Qu X.J., Xie Y.Y., Zhou L., Nakata M., Makuuchi M., and Tang W. Cuicumin inhibits telomerase activity in human cancer cell lines. Int. J. Mol. Med. 18 (2006) 227-231
4. Das M., Rastogi S., and Khanna S.K. Mechanism to study 1:1 stoichiometry of NADPH and alkoxyphenoxazones metabolism spectrophotometrically in subcellular biological preparations. Biochim. Biophys. Acta 1675 (2004) 1-11
5. De, Angelis P.M., Svendsrud D.H., Kravik K.L., and Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol. Cancer. 5 (2006) 20
6. EI-Khoueiry A.B., and Lenz H.J. Should continuous infusion 5-Fluorouracil become the standard of care in the USA as it is in Europe?. Cancer Investig. 24 (2006) 50-55
7. Goto E., Okamoto E., Adachi H., Fukuda Y., and Ito H. Paradoxical effects by preoperative oral low-dose tegafur administration in human gastric carcinomas: enhanced apoptosis and increased intratumoral microvessel density. Oncol. Rep. 9 (2002) 1021-1026
8. Han H.S., Park Y.M., and Hwang T.S. Differential expression of Bcl-2, Bcl-X and p53 in colorectal cancer. J. Gastroenterol. Hepatol. 21 (2006) 1108-1114
9. Hsu L.C., Lee R.M., and White R.L. The HPV16 E6/E7 oncogene sensitizes human ovarian surface epithelial cells to low-dose but not high-dose 5-FU and 5-FUdR. Biochem. Biophys. Res. Commun. 320 (2004) 249-255
10. Inoue Y., Tanaka K., Hiro J., Yoshiyama S., Toiyama Y., Eguchi T., Miki C., and Kusunoki M. In vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. Int. J. Oncol. 28 (2006) 479-486
11. Kametani T., Kigasawa K., Hiiragi M., Wakisaka K., Hagamatsu Y., Sugi H., Fukawa K., Irino O., Yamamoto T., Nishimura N., Taguchi A., Okada T., and Nakayama M. Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl-and N-(alkoxycarbonyl)-5-fluorouracil derivatives. J. Med. Chem. 23 (1980) 1324-1329
12. Krishnaiah Y.S., Satyanarayana V., Dinesh, Kumar B., Karthikeyan R.S., and Bhaskar P. In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur. J. Pharm. Sci. 19 (2003) 355-362
13. Konishi T., Sasaki S., Watanabe T., Kitayama J., and Nagawa H. Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. Oncogenes 25 (2006) 3160-3169
14. Li Q., Feng F.Y., Han J., Sui J.I., Zhu Y.J., Zhang Y., Zhang Z.H., Li L., Wang P.H., Zhou M.Z., and Zhang Y.C. Phase III clinical study of a new anticancer drug atofluding. Ai Zheng. 21 (2002) 1350-1353
15. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
16. Martinez J., Martin C., Chacon M., Korbenfeld E., Bella S., Senna S., Richardet E., Coppola F., Bas C., Hidalgo J., Escobar E., Reale M., Smilovich A., and Wasserman E. Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. Am. J. Clin. Oncol. 29 (2006) 45-51
17. Mitsuhashi H., Suemaru K., Li B., Cui R., and Araki H. Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters. Eur. J. Pharmacol. 551 (2006) 152-155
18. Miyazaki K., Shibahara T., Sato D., Uchida K., Suzuki H., Matsui H., Yanaka A., Nakahara A., and Matsuzaki Y. Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J. Gastroenterol. 41 (2006) 140-150
19. Mo B., and Pater A. Apoptosis, 5-fluorouracil sensitivity and expression of apoptotic proteins in a human ectocervical cell carcinogenesis model using different media. Eur. J. Pharmacol. 467 (2004) 15-22
20. Park J.Y., and Kim K.A. Inhibitory effect of 5-fluorouracil on human cytochrome P (450) isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 59 (2003) 407-409
21. Peet C.F., Enos T., Nave R., Zech K., and Hall M. Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 30 (2005) 275-286
22. Qu X.J., Yang J.L., Russell P.J., and Goldstein D. Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J. Urol. 172 (2004) 733-738
23. Rastogi S., Das M., and Khanna S.K. A novel approach to study the activity and stoichiometry simultaneously for microsomal pentoxyresorufin-O-dealkylase reaction. FEBS Lett. 512 (2002) 121-124
24. Riccardi C., and Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1 (2006) 1458-1461
25. Sassi G., Striano B., and Merlo U.A. A reporting system for the assessment of chemotherapy toxicity. J. Oncol. Pharm. Pract. 11 (2005) 63-67
26. Schmidt Laugesen C., Steffansen B., Scherfig E., and la Cour M. Pharmacokinetics of intravitreal 5-fluorouracil prodrugs in silicone oil: experimental studies in pigs. Acta Ophthalmol. Scand. 83 (2005) 184-190
27. Simeonova M., Velichkova R., Ivanova G., Enchev V., and Abrahams I. Study on the role of 5-fluorouracil in the polymerization of butylcyanoacrylate during the formation of nanoparticles. J. Drug Target. 12 (2004) 49-56
28. Singh S., Chhipa R.R., Vijayyyakumar M.V., and Bhat M.K. DNA damaging drugs-induced down-regulation of Bcl-2 is essential for induction of apoptosis in high-risk HPV-positive HEp-2 and KB cells. Cancer Lett. 236 (2006) 213-221
29. Xu W., Zhang Z., and Castaner J. Atofluding. Drugs Future 26 (2001) 935-938
30. Yim E.K., Lee S.B., Lee K.H., Kim C.J., and Park J.S. Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells. Int. J. Gynecol. Cancer 16 (2006) 1321-1329